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Single Exhaled Breath Metabolomic
Analysis Identifies Unique Breathprint in
Patients With Acute Decompensated Heart Failure
To the Editor: Acute decompensated heart failure (ADHF) is the
most common indication for hospital admission, particularly in the
elderly, yet the identification of those with impending decompen-
sation using conventional clinical methods is unreliable and fre-
quently leaves insufficient lag time for therapeutic interventions
(1). Exhaled breath constitutes a complex mixture of hundreds of
volatile organic compounds (VOCs) that could potentially be used
as a safe and noninvasive method of diagnostic and therapeutic
monitoring (2). Previous research studies have identified elevated
acetone, pentane, and nitric oxide levels in exhaled breath in the
setting of HF correlated with disease severity (3–5). Selected
ion-flow tube mass-spectrometry (SIFT-MS) combines a fast flow
tube technique with quantitative mass spectrometry that is ideally
suited for exhaled breath analysis because it allows for the analysis
of small and humid samples without the need for cumbersome
sample preparation or calibration (6). Scan times are relatively
brief, thus facilitating high throughput and serial comparisons.
Using this technology, we conducted a prospective, single-center
cohort study to assess the feasibility of exhaled breath analysis to
identify patients admitted for ADHF. The study protocol was
approved by the Cleveland Clinic Institutional Review Board. We
recruited 25 consecutive patients admitted with ADHF as their
primary diagnosis (mean left ventricular ejection fraction 27 
13%, median N-terminal pro–B-type natriuretic peptide level 954
pg/ml) and a control group of 16 subjects admitted with non-
ADHF cardiovascular diagnoses and who had no clinical evidence
of systemic or venous congestion at the time of enrollment.
Indications for hospitalization in the control group included
unstable angina or non–ST-segment elevation myocardial infarc-
tion (6 of 16), conduction disorders (3 of 16), hypertensive
emergency (3 of 16), atrial tachyarrhythmia (2 of 16), or stable angina
(2 of 16). All analyses were performed using JMP Pro 9.0 (SAS
Institute, Cary, North Carolina). As expected, there were significant
(p 0.01) baseline differences in the frequency of hypertension (54%
Figure 1 Canonical Discriminant Analysis: ADHF Versus Non-HF Controls
Canonical discriminant analysis using 5 selected mass scanning ion peaks was performed in a training cohort of 25 acute decompensated heart failure (ADHF)
subjects (blue) and 16 controls (red). This ADHF “breathprint” was then used to classify an independent validation cohort of 36 ADHF subjects (green) with no
misclassifications.
vs. 100%) and baseline estimated glomerular filtration rate (68  43 
ml/min/1.73 m2 vs. 102  44 ml/min/1.73 m2), which were signif-
icantly worse in the ADHF versus control group. Nevertheless, there 
were no significant differences between groups in age, body mass 
index, or several comorbidities (i.e., diabetes mellitus, chronic obstruc-
tive pulmonary disease, active smoking) theorized to result in altera-
tions in the exhaled metabolome.
After written informed consent was obtained, exhaled breath 
samples were collected within 24 h of hospital admission and 
following an 8-h fast and before the administration of morning 
pharmacotherapy. Samples were collected after tap water mouth rinse 
to minimize and standardize the contribution of the aerodigestive 
tract. Patients provided a single exhaled vital capacity into a sterile 
mouthpiece while attempting to maintain an exhaled pressure of 15 
millibars. All breath analyses were performed within 2 h of  collection 
using a VOICE200 SIFT-MS instrument (Syft Technologies, 
Christchurch, New Zealand). Pre-specified quantitative assessment of 
acetone and pentane was performed using the SIFT-MS technique. 
Sample collection was well tolerated even among patients with disease 
severity warranting intensive care unit admission and invasive hemo-
dynamic monitoring. Confirming previous reports (3,4), we observed 
increased exhaled acetone (median [interquartile range]: 811 [256 to 
1974] ppb vs. 187 [115 to 572] ppb, p  0.01) and pentane (40 [20 
to 74] ppb vs. 22 [14 to 36] ppb, p  0.03) levels in ADHF versus 
control groups. In addition, mass scanning of ion products for H3O, 
O2
, and NO from 14 to 200 atomic mass units was performed, and 
stepwise variable selection was used to identify 5 ion peaks that were 
incorporated into a canonical discriminant analysis model that suc-
cessfully distinguished ADHF from control patients (2 log likeli-
hood 0.038; Wilks’ Lambda 0.102 [p  0.0001]) (Fig. 1). This 
“breathprint” was then tested in an independent validation cohort of 
36 consecutive ADHF subjects with identical enrollment criteria to 
the derivation cohort. The discriminant analysis model correctly 
classified all subjects with no misclassifications (Fig. 1).
The exhaled metabolome is a temporally dynamic complex 
mixture, and therefore breath analysis is highly susceptible to the 
confounding effects of timing and context of sample collection. In 
addition, methods of metabolomic data analysis (e.g., data reduc-
tion techniques) are still being formalized and will need to be 
refined to facilitate reproducibility and generalizability of future 
studies. Results of this study are limited by the small sample size, 
and larger prospective studies are needed to validate these results. 
Nevertheless, our findings demonstrate the feasibility of single 
exhaled breath analysis in ADHF. In addition, we validated the 
previously reported alterations in acetone and pentane VOC 
concentrations in ADHF, and provided pilot evidence to support 
the hypothesis that a unique ADHF breathprint exists using 
SIFT-MS technology. Once a specific VOC or panel of VOCs is 
identified, highly sensitive and specific solid-state sensors can be 
integrated into portable detectors. Like conventionally available 
exhaled breath sensors, the promise of this technology lies in the 
potential for point-of-care and ambulatory monitoring and screen-
ing. Future studies in exhaled breath metabolomics are needed to 
accelerate progress in the field of cardiovascular medicine.
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Letters to the Editor
Colchicine After Pulmonary Vein
Isolation: Is Inflammation the
New Anti-Arrhythmic Target
We have read with interest the study by Deftereos et al. (1) aimed 
at testing the role of colchicine in preventing atrial fibrillation (AF) 
recurrences in patients with recurrent paroxysmal AF who under-
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